Zoetis Inc. $ZTS Shares Sold by Huntington National Bank

Huntington National Bank cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 27.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 37,206 shares of the company’s stock after selling 14,425 shares during the quarter. Huntington National Bank’s holdings in Zoetis were worth $4,681,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Global Wealth Strategies & Associates acquired a new position in shares of Zoetis during the 4th quarter valued at $25,000. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Zoetis during the 3rd quarter valued at $31,000. Lodestone Wealth Management LLC acquired a new position in shares of Zoetis during the 4th quarter valued at $30,000. Elyxium Wealth LLC acquired a new position in shares of Zoetis during the 4th quarter valued at $32,000. Finally, Holos Integrated Wealth LLC acquired a new position in shares of Zoetis during the 4th quarter valued at $32,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ZTS. UBS Group lowered their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research report on Friday, May 8th. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Bank of America raised their price objective on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Finally, Argus reissued a “hold” rating on shares of Zoetis in a research note on Wednesday. Six equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Zoetis has an average rating of “Hold” and a consensus price target of $133.92.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis presented at the Stifel Jaws & Paws Conference, which may help reassure investors by giving management a venue to discuss strategy, operations, and the path forward. Zoetis Inc. (ZTS) Presents at Stifel Jaws & Paws Conference 2026 Transcript
• Neutral Sentiment: Argus reiterated a “hold” rating on Zoetis, suggesting analysts are not currently seeing a major catalyst for a near-term rebound. Zoetis had its “hold” rating reaffirmed by Argus
• Negative Sentiment: Multiple law firms announced or expanded class action efforts against Zoetis, with investors alleging harm tied to the period from January 14, 2025 through May 6, 2026; these repeated filings keep legal overhang front and center for shareholders. Rosen Law Firm Urges Zoetis Inc. (NYSE: ZTS) Stockholders to Contact the Firm for Information About Their Rights
• Negative Sentiment: The lawsuits stem from Zoetis’ Q1 results, when the company missed earnings and revenue estimates and cut full-year guidance, raising concerns about growth and execution. Zoetis (ZTS) Securities Fraud Investigation – Levi & Korsinsky

Zoetis Stock Performance

ZTS opened at $78.36 on Friday. The firm has a market cap of $32.85 billion, a PE ratio of 12.99, a P/E/G ratio of 1.30 and a beta of 0.87. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The business has a fifty day simple moving average of $105.08 and a 200-day simple moving average of $117.31. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $172.23.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period last year, the business earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is 35.16%.

Insider Transactions at Zoetis

In other Zoetis news, Director Michael B. Mccallister bought 3,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Frank A. Damelio bought 6,650 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, with a total value of $501,343.50. Following the transaction, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 11,650 shares of company stock valued at $886,384 over the last quarter. Company insiders own 0.22% of the company’s stock.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.